EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience

Mônica Gadelha iD, Nelma Verônica Marques, Christhiane Fialho, Cristiane Scaf, Elisa Lamback, Ximene Antunes, Erica Santos, Jaqueline Magalhães, Luiz Eduardo Wildemberg

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgad378 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Mônica Gadelha und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do …. Hauptthemen laut MEDLINE: Acromegaly, Human Growth Hormone, Adenoma. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma, Recordati, Mudskipper Business Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Acromegaly is a rare, chronic, debilitating disorder caused by prolonged hypersecretion of growth hormone (GH) and overproduction of insulin-like growth factor I (IGF-I). Medical therapies, including the somatostatin receptor ligand (SRL) pasireotide, are frequently used to restore biochemical control.

Objective

As patients often receive therapy over prolonged periods, long-term data from real-life settings are needed.

Methods

A retrospective analysis was performed using a prospectively maintained database of all patients with acromegaly from our primary care center who were enrolled in clinical studies with pasireotide (first visit November 2008). The main outcome measures were safety and biochemical control (age-adjusted IGF-I ≤ upper limit of normal).

Results

Patients (n = 50) entered 4 parental studies and 30 continued in the rollover; at data cutoff (June 2022), 27 were still receiving pasireotide. Overall, median (range) exposure was 58 (3-137) months. Normal IGF-I was achieved in 54%, and acromegaly symptoms and quality of life were improved with treatment. No predictors of pasireotide response were identified; however, controlled patients had smaller tumors and lower GH at baseline. Tumor volume reduction occurred in 63% of evaluable patients (n = 10/16). Most patients presented hyperglycemic events, including 63.2% of patients with normal glucose before treatment. Older patients and those with higher IGF-I, glucose, and HbA1c at baseline had higher glucose and HbA1c during pasireotide treatment.

Conclusion

Pasireotide provided clinical benefit and was well tolerated for more than 11 years of treatment in acromegaly patients, most of whom were resistant to first-generation SRLs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyHuman Growth HormoneAdenomaHumansInsulin-Like Growth Factor IGlycated HemoglobinRetrospective StudiesQuality of LifeTreatment OutcomeGrowth HormoneGlucoseSomatostatin

Stichwörter der Autor:innen

acromegalylong termpasireotidereal worldretrospective

Substanzen

Insulin-Like Growth Factor IGlycated HemoglobinHuman Growth HormoneGrowth HormoneGlucosepasireotideSomatostatin

Autor:innen und Institutionen

  • Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.

ORCID-Profile: Mônica Gadelha

Förderung

  • Novartis Pharma
  • Recordati
  • Mudskipper Business Ltd

Zitieren

APA

Gadelha, M., Marques, N. V., Fialho, C., Scaf, C., Lamback, E., Antunes, X., Santos, E., Magalhães, J., & Wildemberg, L. E. (2023). Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad378

Vancouver

Gadelha M, Marques NV, Fialho C, Scaf C, Lamback E, Antunes X, et al. Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad378

BibTeX
@article{Gadelha2023,
  author = {Gadelha, Mônica and Marques, Nelma Verônica and Fialho, Christhiane and Scaf, Cristiane and Lamback, Elisa and Antunes, Ximene and Santos, Erica and Magalhães, Jaqueline and Wildemberg, Luiz Eduardo},
  title = {Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgad378}
}
Kostenlos starten →